A Phase I/II Dose Escalation Trial Of HDAC Inhibitor Tefinostat (CHR2845) For Cancer Associated Inflammation In Hepatocellular Carcinoma
Read time: 1 mins
Last updated:11th May 2012
Phase I: To determine the safety, tolerability and dose-limiting toxicities (DLT) of tefinostat when administered orally to patients with advanced HCC To determine the recommended Phase II dose (RP2D) of tefinostat in patients with advanced HCC Phase II: To perform a preliminary assessment of the anti-disease activity of tefinostat as measured by mRECIST.
|Study start date||2012-05-11|